WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2015124867) COMPOSITIONS FOR PREVENTING AND/OR TREATING PATHOLOGICAL CONDITIONS ASSOCIATED WITH ALPHA-GLUCOSIDASE
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2015/124867 International Application No.: PCT/FR2015/050397
Publication Date: 27.08.2015 International Filing Date: 18.02.2015
IPC:
A61K 38/05 (2006.01) ,A61K 38/06 (2006.01) ,A61P 3/10 (2006.01)
Applicants: UNIVERSITÉ DE LA ROCHELLE[FR/FR]; Technoforum-23, avenue Albert Einstein BP 33060 F-17031 La Rochelle, FR
UNIVERSITÉ BLAISE PASCAL-CLERMONT II[FR/FR]; 34, avenue Carnot F-63006 Clermont-Ferrand Cedex 01, FR
Inventors: MAUGARD, Thierry; FR
BORDENAVE-JUCHEREAU, Stéphanie; FR
PIOT, Jean-Marie; FR
BEN-HENDA, Yesmine; FR
SIRVENT, Pascal; FR
PELTIER, Sébastien; FR
Agent: GROSSET-FOURNIER, Chantal; FR
Priority Data:
14/5128018.02.2014FR
Title (EN) COMPOSITIONS FOR PREVENTING AND/OR TREATING PATHOLOGICAL CONDITIONS ASSOCIATED WITH ALPHA-GLUCOSIDASE
(FR) COMPOSITIONS POUR LA PRÉVENTION ET/OU LE TRAITEMENT DE PATHOLOGIES LIÉES A L'ALPHA-GLUCOSIDASE
Abstract:
(EN) The invention relates to a composition comprising at least one XAP peptide, in which X is the empty set or a valine, for use thereof in preventing and/or treating pathological conditions associated with alpha-glucosidase. The invention also relates to the use of a hydrolysate of at least one protein, said protein comprising or consisting of at least 0.05% to <5% or of at least 5% of XAP units, in which X is the empty set or a valine, for use thereof in preventing and/or treating pathological conditions associated with alpha-glucosidase.
(FR) L'invention concerne une composition comprenant au moins un peptide XAP, dans lequel X représente l'ensemble vide ou une valine, pour son utilisation dans la prévention et/ou le traitement de pathologies liées à l'alpha-glucosidase. L'invention concerne aussi l'utilisation d'un hydrolysat d'au moins une protéine, ladite protéine comportant ou étant constituée d'au moins 0,05% à <5% ou d'au moins 5% de motifs XAP, dans lequel X représente l'ensemble vide ou une valine, pour son utilisation dans la prévention et/ou le traitement de pathologies liées à l'alpha-glucosidase.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: French (FR)
Filing Language: French (FR)